JP6037388B2 - 疾患サンプル分析装置、分析システム及び分析方法 - Google Patents

疾患サンプル分析装置、分析システム及び分析方法 Download PDF

Info

Publication number
JP6037388B2
JP6037388B2 JP2013055673A JP2013055673A JP6037388B2 JP 6037388 B2 JP6037388 B2 JP 6037388B2 JP 2013055673 A JP2013055673 A JP 2013055673A JP 2013055673 A JP2013055673 A JP 2013055673A JP 6037388 B2 JP6037388 B2 JP 6037388B2
Authority
JP
Japan
Prior art keywords
mice
amino acid
concentration
disease
urine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013055673A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013224929A5 (OSRAM
JP2013224929A (ja
Inventor
健司 浜瀬
健司 浜瀬
洋介 東條
洋介 東條
真史 三田
真史 三田
智恵子 水本
智恵子 水本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyushu University NUC
Shiseido Co Ltd
Original Assignee
Kyushu University NUC
Shiseido Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyushu University NUC, Shiseido Co Ltd filed Critical Kyushu University NUC
Priority to JP2013055673A priority Critical patent/JP6037388B2/ja
Publication of JP2013224929A publication Critical patent/JP2013224929A/ja
Publication of JP2013224929A5 publication Critical patent/JP2013224929A5/ja
Application granted granted Critical
Publication of JP6037388B2 publication Critical patent/JP6037388B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/89—Inverse chromatography
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8818—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8877—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2013055673A 2012-03-18 2013-03-18 疾患サンプル分析装置、分析システム及び分析方法 Active JP6037388B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013055673A JP6037388B2 (ja) 2012-03-18 2013-03-18 疾患サンプル分析装置、分析システム及び分析方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012061305 2012-03-18
JP2012061305 2012-03-18
JP2013055673A JP6037388B2 (ja) 2012-03-18 2013-03-18 疾患サンプル分析装置、分析システム及び分析方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016209988A Division JP6214016B2 (ja) 2012-03-18 2016-10-26 疾患サンプル分析装置、分析システム及び分析方法

Publications (3)

Publication Number Publication Date
JP2013224929A JP2013224929A (ja) 2013-10-31
JP2013224929A5 JP2013224929A5 (OSRAM) 2016-06-23
JP6037388B2 true JP6037388B2 (ja) 2016-12-07

Family

ID=49222264

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013055673A Active JP6037388B2 (ja) 2012-03-18 2013-03-18 疾患サンプル分析装置、分析システム及び分析方法
JP2016209988A Active JP6214016B2 (ja) 2012-03-18 2016-10-26 疾患サンプル分析装置、分析システム及び分析方法
JP2017175949A Active JP6391787B2 (ja) 2012-03-18 2017-09-13 疾患サンプル分析装置、分析システム及び分析方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016209988A Active JP6214016B2 (ja) 2012-03-18 2016-10-26 疾患サンプル分析装置、分析システム及び分析方法
JP2017175949A Active JP6391787B2 (ja) 2012-03-18 2017-09-13 疾患サンプル分析装置、分析システム及び分析方法

Country Status (7)

Country Link
US (2) US20150079623A1 (OSRAM)
EP (3) EP3663758A1 (OSRAM)
JP (3) JP6037388B2 (OSRAM)
CN (11) CN110133296B (OSRAM)
IN (1) IN2014MN02060A (OSRAM)
TW (2) TWI664425B (OSRAM)
WO (1) WO2013140785A1 (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5740523B1 (ja) 2013-12-11 2015-06-24 株式会社 資生堂 腎不全の早期診断マーカー
SG10201911910RA (en) * 2015-06-10 2020-02-27 Univ Kanazawa Disease-state biomarker for renal disease
CN108486028B (zh) * 2015-10-10 2021-06-01 中国科学院南海海洋研究所 一种高产含有L-Val结构单元的化合物的菌株△mfnH
SG11201810254UA (en) * 2016-05-17 2018-12-28 Univ Osaka Blood sample analysis method and system, for determining diabetes
CN109154621B (zh) * 2016-05-17 2022-08-05 国立大学法人大阪大学 肾脏病的预后预测方法及系统
AU2017361186A1 (en) 2016-11-15 2019-06-13 Shiseido Company, Ltd. Multidimensional chromatographic analysis method and analysis system
WO2018159833A1 (ja) * 2017-03-02 2018-09-07 株式会社ニコン 細胞の判別方法、がんの検査方法、計測装置、がんの検査装置および検査プログラム
EP3590937A4 (en) 2017-03-03 2021-03-10 Shiseido Company Ltd. NOVEL COMPOUND, FLUORESCENT DERIVATIZATION REAGENT WITH THE ABOVE NOVEL COMPOUND, METHOD OF OPTICAL RESOLUTION OF AN OPTICAL ISOMER OF AMINO ACID USING THE ABOVE NOVEL COMPOUND, AND FLUORESCENT
US12220394B2 (en) 2018-06-07 2025-02-11 National University Corporation Kanazawa University Pharmaceutical composition for prevention or treatment of kidney damage
WO2020045364A1 (ja) * 2018-08-27 2020-03-05 株式会社 資生堂 乾癬を判定するための皮膚試料の分析方法及びシステム
CN113196062A (zh) 2018-10-17 2021-07-30 镜株式会社 肾小球滤过能力的确定方法
US12480954B2 (en) 2019-03-22 2025-11-25 Kagami Inc. Method for assisting evaluation of condition of kidneys, system for evaluating condition of kidneys, and program for evaluating condition of kidneys
JP7733909B2 (ja) * 2019-03-22 2025-09-04 Kagami株式会社 腎病態の評価を補助する方法、腎病態の評価システム及び腎病態の評価プログラム
JP7434678B2 (ja) * 2019-05-20 2024-02-21 花王株式会社 認知症又はそのリスクの検査方法
US20230037869A1 (en) 2019-12-27 2023-02-09 Kagami Inc. Method and system for estimating renal function
CN112180007B (zh) * 2020-09-16 2023-08-18 上海市皮肤病医院 基于代谢组学的泛发性脓疱型银屑病诊断标志物及其应用
CN111899883B (zh) * 2020-09-29 2020-12-15 平安科技（深圳）有限公司 少样本或零样本的疾病预测设备、方法、装置及存储介质
JP7600016B2 (ja) * 2021-03-30 2024-12-16 花王株式会社 高次脳機能の測定方法
US20250003971A1 (en) * 2021-09-03 2025-01-02 Kagami Inc. Method for providing information pertaining to cancer, system for providing information pertaining to cancer, and method for treating cancer

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4290893A (en) * 1979-05-08 1981-09-22 Yeda Research & Development Co. Ltd. Separation of amino acids by liquid chromatography using chiral eluants
CA2030212A1 (en) * 1989-11-22 1991-05-23 Judson V. Edwards Peptides
US5374651A (en) * 1991-09-27 1994-12-20 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of hypotension with arginine free essential and essential amino acids and arginine derivatives
WO1996028470A2 (en) * 1995-03-09 1996-09-19 Neurocrine Biosciences, Inc. Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
JPH0975078A (ja) * 1995-09-13 1997-03-25 Ikeda Shokken Kk 耐熱性ｄ−アミノ酸オキシダーゼ、その製造法および微生物
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
EP0882736A1 (en) * 1997-06-02 1998-12-09 Laboratoire Theramex S.A. LH-RH peptide analogues, their uses and pharmaceutical compositions containing them
EP1085885B1 (en) * 1998-06-11 2003-10-01 Fox Chase Cancer Center Method for assessing a diabetic's risk of experiencing a diabetes-associated pathologic condition
WO2000070329A1 (en) * 1999-05-14 2000-11-23 Brandeis University Nucleic acid-based detection
US6479063B2 (en) * 1999-12-27 2002-11-12 Kenneth Weisman Therapeutic uses of hormonal manipulation using combinations of various agents to treat atherosclerosis
US7223558B2 (en) * 2001-07-11 2007-05-29 Bristol-Myers Squibb Company Polynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunologobulin folds, BGS2, 3, and 4 and variants thereof
FR2828693B1 (fr) * 2001-08-14 2004-06-18 Exonhit Therapeutics Sa Nouvelle cible moleculaire de la neurotoxicite
WO2003072059A2 (en) * 2002-02-27 2003-09-04 Wake Forest University Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
FR2838444B1 (fr) * 2002-04-10 2016-01-01 Neovacs Nouveaux peptides et leur application en therapeutique
US20070298041A1 (en) * 2002-06-28 2007-12-27 Tomlinson Ian M Ligands That Enhance Endogenous Compounds
EP1542017A4 (en) * 2002-07-04 2007-07-11 Mitsubishi Pharma Corp METHOD FOR EXAMINING AND DIAGNOSING THE INTEGRATION ERROR SYNDROME
GB0219776D0 (en) * 2002-08-24 2002-10-02 Oxford Glycosciences Uk Ltd A protein involved in carcinoma
GB0223424D0 (en) * 2002-10-09 2002-11-13 Imp College Innovations Ltd Disease-associated gene
CA2508136A1 (en) * 2002-12-09 2004-06-24 Ajinomoto Co., Inc. Apparatus and method for processing information concerning biological condition, system, program and recording medium for managing information concerning biological condition
WO2004063221A1 (ja) * 2002-12-26 2004-07-29 Takeda Pharmaceutical Company Limited メタスチン誘導体およびその用途
AU2003900777A0 (en) * 2003-02-21 2003-03-13 Medvet Science Pty. Ltd. A method of diagnosis and treatment
EP1601948A2 (en) * 2003-03-10 2005-12-07 Sionex Corporation Systems for differential ion mobility analysis
CA2521221A1 (en) * 2003-04-02 2004-10-14 Genix Therapeutics, Inc. Method for the treatment of prostate cancer
JP4291628B2 (ja) 2003-06-12 2009-07-08 株式会社資生堂 液体クロマトグラフ装置及び試料に含まれる光学異性体の分析方法
CN1557823A (zh) * 2004-02-12 2004-12-29 窦德献 L-或d-氨基酸合铂配位体、制备方法及其用途
US7901881B2 (en) * 2004-04-09 2011-03-08 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic tool for diagnosing benign versus malignant thyroid lesions
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
GB0417887D0 (en) * 2004-08-11 2004-09-15 Ares Trading Sa Protein
US9063157B2 (en) * 2005-03-18 2015-06-23 Shiseido Company, Ltd. Method for evaluating skin condition using squamous cell carcinoma antigen as marker
CN101189243A (zh) * 2005-04-06 2008-05-28 阿斯利康(瑞典)有限公司 取代的杂环及其作为chk1、pdk1和pak抑制剂的应用
JP2007077104A (ja) * 2005-09-16 2007-03-29 Shiseido Co Ltd 血管内皮増殖因子阻害剤
DK1996923T3 (da) * 2006-03-02 2012-10-01 Perkinelmer Health Sci Inc Fremgangsmåder til adskillelse af isomerer ved hjælp af massespektrometri
US20070258899A1 (en) * 2006-03-31 2007-11-08 Karyon-Ctt Ltd Diagnostic and therapeutic agents
JP5005955B2 (ja) * 2006-05-24 2012-08-22 田辺三菱製薬株式会社 被験物質の脂質代謝異常症誘発可能性を予測する方法
JP5399900B2 (ja) * 2006-06-30 2014-01-29 メルク・シャープ・アンド・ドーム・コーポレーション Ｉｇｆｂｐ２インヒビター
EP1900742A1 (en) * 2006-09-07 2008-03-19 AEterna Zentaris GmbH Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
BRPI0716190A2 (pt) * 2006-09-06 2013-11-12 Aeterna Zentaris Gmbh Conjugados de disorazóis e seus derivados com móleculas de ligação celular, derivados de disorazol, processos para fabricação e uso dos mesmos
US20090075284A1 (en) * 2006-09-19 2009-03-19 The Regents Of The University Of Michigan Metabolomic profiling of prostate cancer
JP2010516697A (ja) * 2007-01-18 2010-05-20 セプラコール インク． Ｄ−アミノ酸オキシダーゼ阻害剤
JP2010518812A (ja) * 2007-02-12 2010-06-03 アンスロジェネシス コーポレーション 接着性胎盤幹細胞由来の肝細胞および軟骨細胞、ならびにｃｄ３４＋、ｃｄ４５−胎盤幹細胞の濃縮細胞集団
US8034780B2 (en) * 2007-07-16 2011-10-11 Mcphail Kerry Leigh Isolation, purification, and structure elucidation of the antiproliferative compound coibamide A
EP2239576A1 (en) * 2008-01-17 2010-10-13 Toray Industries, Inc. Composition and method for diagnosis or detection of gastric cancer
JP2009184981A (ja) * 2008-02-07 2009-08-20 Shiseido Co Ltd 抗ｄ−アミノ酸モノクローナル抗体及び、抗ｄ−アミノ酸モノクローナル抗体を用いたｄ−アミノ酸の免疫学的分析方法
US20100112089A1 (en) * 2008-05-14 2010-05-06 Takeda Pharmaceutical Company Limited Peptide compound and use thereof
WO2009143489A2 (en) * 2008-05-22 2009-11-26 Archer Pharmaceuticals, Inc. Modulation of angiogenesis by a-beta peptide fragments
US20110311650A1 (en) * 2008-07-07 2011-12-22 Thomas Wang Multiplexed biomarkers of insulin resistance
JP2010038796A (ja) * 2008-08-06 2010-02-18 Human Metabolome Technologies Inc 疾患マーカー、および、疾患マーカーの測定方法
WO2010024091A1 (ja) * 2008-08-26 2010-03-04 国立大学法人九州大学 Ｄａｏ１－／－マウスを活用したＤ－アミノ酸関連疾患の評価・スクリーニング方法
US8722343B2 (en) * 2008-11-21 2014-05-13 Carla Perego Methods and compositions for the diagnosis and treatment of diabetes
EP2249161B1 (en) * 2009-05-05 2020-05-13 InfanDx AG Method of diagnosing asphyxia
CN101619092B (zh) * 2009-08-06 2012-08-15 中国人民解放军第三军医大学第二附属医院 肿瘤抗原trag-3模拟表位肽及其应用
US20110064828A1 (en) * 2009-09-11 2011-03-17 Novelos Therapeutics, Incorporated Treatment of metastatic tumors and other conditions
JP2011247869A (ja) * 2010-04-27 2011-12-08 Kobe Univ メタボローム解析手法を用いた特定疾患の検査方法
CN102079771B (zh) * 2010-12-10 2012-10-03 郑州大学 具有抗肿瘤活性的雌甾氨基酸酯化合物及其合成方法

Also Published As

Publication number Publication date
JP6391787B2 (ja) 2018-09-19
EP3795997A1 (en) 2021-03-24
TWI615614B (zh) 2018-02-21
JP2017223711A (ja) 2017-12-21
CN110133296B (zh) 2022-03-25
EP3795997B1 (en) 2022-08-24
TW201736851A (zh) 2017-10-16
CN110133301A (zh) 2019-08-16
CN110133300B (zh) 2022-02-25
JP2013224929A (ja) 2013-10-31
CN110133298A (zh) 2019-08-16
EP2829877A4 (en) 2015-12-09
CN110133300A (zh) 2019-08-16
WO2013140785A1 (ja) 2013-09-26
JP2017015741A (ja) 2017-01-19
CN104246497A (zh) 2014-12-24
JP6214016B2 (ja) 2017-10-18
CN114966050A (zh) 2022-08-30
CN110161256B (zh) 2022-03-25
CN110133301B (zh) 2022-03-22
TW201344194A (zh) 2013-11-01
CN110161256A (zh) 2019-08-23
CN110133299A (zh) 2019-08-16
CN107449923B (zh) 2020-07-24
TWI664425B (zh) 2019-07-01
EP2829877A1 (en) 2015-01-28
CN104246497B (zh) 2017-10-13
EP2829877B1 (en) 2020-01-22
CN107449923A (zh) 2017-12-08
CN110133297A (zh) 2019-08-16
CN110133296A (zh) 2019-08-16
US20190025320A1 (en) 2019-01-24
US20150079623A1 (en) 2015-03-19
CN110133295A (zh) 2019-08-16
EP3663758A1 (en) 2020-06-10
IN2014MN02060A (OSRAM) 2015-08-21

Similar Documents

Publication Publication Date Title
JP6391787B2 (ja) 疾患サンプル分析装置、分析システム及び分析方法
JP2013224929A5 (OSRAM)
US20190339281A1 (en) Marker for early diagnosis of kidney failure
Zhong et al. Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice
CN109154621B (zh) 肾脏病的预后预测方法及系统
Hesaka et al. d-Serine mediates cellular proliferation for kidney remodeling
CN109154619A (zh) 用于判定糖尿病的血液试样的分析方法及系统
CN107683414A (zh) 肾病的病态生物标志物
JP5877862B2 (ja) Ｄａｏ１−／−マウスを活用したＤ−アミノ酸関連疾患の評価・スクリーニング方法
Zha et al. A fast and efficient liquid chromatography–tandem mass spectrometry method for measuring l‐and d‐amino acids in the urine of patients with immunoglobulin A nephropathy
JPWO2005012570A1 (ja) Ｓｌｃ２５ａ１０による肥満治療に有効な化合物の評価方法
JP2025013689A (ja) 猫の腎機能障害の検査方法
HK40002816A (en) Kidney disease prognosis prediction method and system

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141017

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7421

Effective date: 20150121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160509

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20160509

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20160601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160905

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160927

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161026

R150 Certificate of patent or registration of utility model

Ref document number: 6037388

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250